

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Entacapone Tablets (0.2g) from National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities.

As stated in the Company’s announcement dated 27 September 2023, the Group’s Entacapone bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Entacapone Tablet is mainly used in combination with Levodopa for the treatment of Parkinson’s disease and its end-of-dose phenomenon (fluctuations in symptoms).

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 3 June 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.